Protocol Ledger

NCT06635148 · Phase II/III · RECRUITING

A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Interventional Phase II/III clinical trial protocol NCT06635148 sponsored by Johnson & Johnson / Janssen in Ophthalmology and Sensory, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-09-19 Enrollment: 274 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06635148
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)274 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06635148
Protocol FieldVerified Registry Value
NCT IdentifierNCT06635148
Consolidated Lead SponsorJohnson & Johnson / Janssen
Therapeutic Condition CohortOphthalmology and Sensory
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment274 participants (ESTIMATED)
Registered Start Date2024-09-19
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06635148
Hospital Research SiteLocationSite Profile
Retina Consultants of Orange CountyFullerton, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Ophthalmology and Sensory Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI